Medication uses during the 2 weeks preceding out-of-hospital cardiac arrest
No survived event (n=918) | Survived event (n=463) | p Value | |
---|---|---|---|
Antiarrhythmics | |||
Class I | 6 (0.7) | 3 (0.6) | 1.000 |
Class II | 29 (3.2) | 26 (5.6) | 0.028* |
Class III | 7 (0.8) | 3 (0.6) | 1.000 |
Class IV | 63 (6.9) | 34 (7.3) | 0.741 |
Aspirin | 54 (5.9) | 31 (6.7) | 0.553 |
Clopidogrel | 23 (2.5) | 16 (3.5) | 0.314 |
Statin | 26 (2.8) | 23 (5.0) | 0.043* |
Nitroglycerin | 23 (2.5) | 15 (3.2) | 0.431 |
Insulin | 10 (1.1) | 8 (1.7) | 0.323 |
Oral hypoglycemic agents | 65 (7.1) | 42 (9.1) | 0.191 |
α-Blockers | 17 (1.9) | 16 (3.5) | 0.065 |
Angiotensin receptor blockers | 58 (6.3) | 40 (8.6) | 0.113 |
ACE inhibitors | 19 (2.1) | 9 (1.9) | 0.875 |
Diuretics | 97 (10.6) | 52 (11.2) | 0.707 |
Warfarin | 9 (1.0) | 4 (0.9) | 1.000 |
Magnesium | 14 (1.5) | 9 (1.9) | 0.566 |
Erythromycin | 2 (0.2) | 1 (0.2) | 1.000 |
N-acetylcysteine | 5 (0.5) | 8 (1.7) | 0.040* |
Steroid | 17 (1.9) | 8 (1.7) | 0.870 |
Digoxin | 34 (3.7) | 8 (1.7) | 0.044* |
Theophylline | 39 (4.2) | 19 (4.1) | 0.899 |
Cilostazol | 5 (0.5) | 1 (0.2) | 0.670 |
QT-prolonging drugs | 10 (1.1) | 5 (1.1) | 0.987 |
Data were presented as count (percentage).
*p<0.05.